Market research
1521.HK Frontage Holdings Corporation
HK HKD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3B
- P/E ratio
- 43.0
- Analyst target
- 0.9721
- Dividend yield
- Not available
- Beta
- 0.22
Profile
Company facts
- Exchange
- HK
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- KYG3679P1019
- Market cap
- 3B
- P/E ratio
- 43.0
- Analyst target
- 0.9721
- Dividend yield
- Not available
- Beta
- 0.22
About
About Frontage Holdings Corporation
Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug metabolism and pharmacokinetics (DMPK); safety and toxicology; early phase clinical services; and bioequivalence and related services, such as pharmacology, medical writing, and regulatory support. In addition, it offers pharmaceutical product development services, including intermediate and active pharmaceutical ingredient (API) synthesis, process and formulation development, and clinical trial material manufacturing. Further, the company provides laboratory testing services, such as bioanalysis, biomarkers, genomics, chemistry, manufacturing and controls ("CMC") analytical testing, and central laboratory services. It operates in the United States, Canada, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. The company was founded in 2001 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation operates as a subsidiary of Hongkong Tigermed Consulting Co., ltd.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 1521.HK discussion.
5 years, 5 months ago
Frontage Holdings Corporation is currently in a long term uptrend where the price is trading 42.4% above its 200 day moving average.
From a valuation standpoint, the stock is 90.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.2.
Frontage Holdings Corporation's total revenue sank by 0.1% to $51M since the same quarter in the previous year.
Its net income has dropped by 51.8% to $4M since the same quarter in the previous year.
Finally, its free cash flow grew by 170.7% to $6M since the same quarter in the previous year.
Based on the above factors, Frontage Holdings Corporation gets an overall score of 3/5.